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ABSTRACT
Off-therapy control of viremia by HIV-infected individuals has been associated with two likely players: a restricted viral reser-
voir and an efficient cell-mediated immune response. We previously showed that a combination of highly suppressive antiretro-
viral therapy and two experimental drugs, i.e., auranofin and buthionine sulfoximine, was able to reduce the viral reservoir, elicit
efficient cell-mediated antiviral responses, and induce intermittent posttherapy viral load control in chronically SIVmac251-
infected macaques. We here show that the macaques that had received this drug combination and then stopped antiretroviral
therapy were also able to maintain low numbers of activated CD4 T cells at viral rebound. Moreover, these macaques consis-
tently displayed low-level simian immunodeficiency virus (SIV) diversity, which was in line with the strong and broadly reactive
cell-mediated immune responses against conserved Gag antigens. Extended follow-up showed that the twomacaques that had
received the complete drug combination remained healthy and did not develop AIDS in 2 years of follow-up after therapy sus-
pension. This disease-free survival is longer than twice the average time of progression to AIDS in SIVmac251-infected rhesus
macaques. These results suggest that limited numbers of activated T cells at viral rebound and subsequent development of
broadly reactive cell-mediated responses may be interrelated in reducing the viral reservoir.
IMPORTANCE
The HIV reservoir in CD4 T cells represents one main obstacle to HIV eradication. Recent studies, however, show that a drastic
reduction of this reservoir is insufficient for inducing a functional cure of AIDS. In the present work, we thoroughly studied and
subjected to long-term follow-up twomacaques showing intermittent control of the virus following suspension of antiretroviral
therapy plus an experimental antireservoir treatment, i.e., the gold salt auranofin and the investigational chemotherapeutic
agent buthionione sulfoximine (BSO). We found that these drugs were able to decrease the number of activated CD4 T cells,
which are preferential targets for HIV infection. Then, efficient immune responses against the virus were developed in the ma-
caques, which remained healthy during 2 years of follow-up. This result may furnish another building block for future attempts
to cure HIV/AIDS.
Afunctional cure is a state “in which the virus is not eliminatedbut is controlled effectively by antiviral immune responses so
that drug treatment can be withdrawn for prolonged periods of
time” (1, 2). Controlled studies in monkeys infected with simian
immunodeficiency virus (SIV) or simian-human immunodefi-
ciency virus (SHIV) and anecdotal reports on human immunode-
ficiency virus type 1 (HIV-1)-infected humans, such as the “Bos-
ton patients” and the “Mississippi baby,” have shown that
reduction of the viral reservoir, or inhibition of its formation, is a
crucial factor for controlling viral load in the absence of antiret-
roviral therapy (ART) but is not its only determinant (3–6). These
reports suggest that without complete eradication of the viral res-
ervoir, viral load control in the absence of therapy is transient or
incomplete. Thus, efficient immune responses are likely pivotal to
obtain a long-lasting effect on viral load in the chronic phase of the
disease, although they may not be essential in posttherapy control-
lers treated during acute infection (7).
One missing link between restriction of the viral reservoir and
development of efficient immune responses could be modulation
of immune activation. In this context, some of us focused atten-
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tion on auranofin, a gold-based compound used to decrease im-
mune activation in individuals with rheumatoid arthritis (4, 8, 9).
Auranofin decreases immune activation, likely by causing down-
modulation of the costimulatory molecule CD28 in T cells (8).
Downmodulation of CD28 is accompanied by a decreased life
span of central and transitional memory T cells (TCM and TTM
cells) encompassing the viral reservoir (4, 8). In a first in vivo
study, a combination of ART and auranofin induced, in the post-
therapy follow-up, a peak in viral load, reminiscent of a novel
acute infection, followed by a significant yet moderate decrease in
the posttherapy viral load set point (4). A subsequent study repro-
duced these effects, and in some animals, the initial viral load peak
and the related immune activation were blunted by a short cycle of
ART containing maraviroc, a drug that also impacts immune ac-
tivation (10). Following the second treatment interruption, these
macaques showed intermittent control of viremia to undetectable
levels, which was, however, lost in the long term. By adding to the
auranofin-containing ART regimen buthionine sulfoximine
(BSO) (originally intended to kill the infected cells), an intermit-
tent posttherapy control of viral load to undetectable levels was
obtained in the macaques that had received this treatment, and
this control was not lost during the entire follow-up period (11).
Surprisingly, this functional cure-like condition showed depen-
dence on an unexpected development of CD8 cell-mediated im-
mune responses (11), but the mechanism behind the immune
responses evoked by auranofin and BSO has remained elusive.
The working hypothesis behind the present study is that with-
out these experimental treatments, immune hyperactivation at
viral rebound following suspension of ART might spark noneffi-
cient immunodominant responses, thus creating a sort of “immu-
nological junk” rendering the immune system inefficient. There is
growing consensus that not all of the antiviral immune responses
contribute to immune control of the virus and that some clones
directed against conserved epitopes may efficiently mediate viral
clearance (12, 13). Limitation of immune activation might there-
fore contribute to viral load control.
Here, we show that in the aforementioned macaques treated
with ART, auranofin, and BSO (11), immune activation is limited
during the posttherapy viral rebound. This phenomenon was as-
sociated with broadly reactive immune responses against con-
served Gag epitopes and limited SIV evolution and replication
throughout the follow-up. These results might provide some clues
for curing HIV in humans.
MATERIALS AND METHODS
Animal treatment. Animals were housed at Bioqual, Inc., according to
standards and guidelines as set forth in the Animal Welfare Act, the Guide
for the Care and Use of Laboratory Animals, and the Association for the
Assessment and Accreditation of Laboratory Animal Care (AAALAC),
following approval by the Institutional Animal Care and Use Committee
(IACUC). No treatments were administered during the follow-up dis-
played in the present article, apart from short-term antibiotic prophylaxes
in case animals in proximal cages developed bacterial infections. Details
on previous treatments, dosages, and rationale have been extensively pro-
vided previously (10, 11). and the relevant information is summarized in
Table 1 and Fig. 1. Control macaques were selected on the basis of avail-
ability of frozen peripheral blood mononuclear cell (PBMC) samples.
Separation of PBMCs, isolation of primary T cells, and in vitro cell
cultivation. To test the effects of the combination of auranofin and BSO
on survival of activated CD4 and CD8T cells, we devised a set of in vitro
experiments. PBMCs from healthy donors were isolated from whole
blood by density gradient centrifugation using Ficoll-Paque. CD4 and
CD8T cells were isolated by positive selection with specific isolation kits
(Miltenyi Biotec). Both isolated CD4 and CD8 T cells were cultured in
12-well plates at a concentration of 1 106 cells/ml per well. The culturing
medium employed was RPMI 1640 supplemented with 10% fetal bovine
serum (FBS) and, in the appropriate wells, further complemented with
auranofin (250 nM), BSO (250M), or a combination of the two. After 24
h (day 1), cells were activated with phytohemagglutinin (PHA) (2g/ml)
or anti-CD3 (-CD3)/-CD28 antibodies (5 g/ml; BioLegend, San Di-
ego, CA, USA). For -CD3/-CD28-mediated activation, cells were
transferred to a plate precoated with the antibodies for 12 h before use. In
all experiments, one cell culture was left nonactivated to serve as a control.
Cells were maintained in an incubator at 37°C in a 5% CO2 atmosphere.
Flow cytometric analysis. After 72 h of culture (day 3), CD4 and
CD8 T cells cultured in vitro were collected and stained for viability and
expression levels of the alpha chain of the interleukin-2 (IL-2) receptor
(i.e., CD25), a marker chosen to confirm the results of previous experi-
ments (14). Briefly, the cells (3  105 per sample) were initially surface
stained with saturating concentrations of an -CD25 antibody (phyco-
erythrin [PE] conjugated; BD Biosciences, Franklin Lakes, NJ, USA) for
20 min at 4°C in magnetically activated cell sorting (MACS) buffer. After-
wards, cells were washed in phosphate-buffered saline (PBS), stained with
annexin V (allophycocyanin [APC] conjugated; Sigma-Aldrich, St. Louis,
MO, USA) for 10 min at room temperature in an appropriate buffer
provided by the manufacturer, and eventually resuspended in 1% para-
formaldehyde in PBS. Fluorescence was acquired flow cytometrically (BD,
Franklin Lakes, NJ, USA) and analyzed using the FACSDiva software (BD,
Franklin Lakes, NJ, USA).
For measurement of the number of activated T cells in vivo, 3  105
macaque PBMCs were stained for 20 min at 4°C in MACS buffer using
anti-CD3 (fluorescein isothiocyanate [FITC] conjugated), anti-CD4 (PE
conjugated), anti-CD8 (peridinin chlorophyll protein [PerCP]-Cy5 con-
jugated), and anti-HLA-DR (APC conjugated), as previously described
(10). All antibodies were purchased from BD (Franklin Lakes, NJ, USA).
The flow cytometric analysis was conducted on a FACSCanto II instru-
ment (BD, Franklin Lakes, NJ, USA).
For measurement of T cell-dependent NK cell effector responses, 1
1 105 to 1  105 macaque PBMCs were stimulated with SIVmac239
Gag peptides (complete set of 15-mer peptides overlapping by 11
amino acids and spanning the entire protein; NIH AIDS Research and
Reference Reagent Program, Germantown, MD) for 24 h as previously
described (15, 16). Rhesus cytokine-producing NK cells were identi-
fied as live CD3 CD8 CD159a CD56 cells. Nonstimulated and
staphylococcal enterotoxin B (SEB) (5 l/ml; Sigma)-treated tubes
were used as negative and positive controls, respectively.
MTS assay. In our in vitro experiments, we eventually measured the
overall cell viability after 96 h of culture (day 4) with a colorimetric assay
employing the tetrazolium compound 3-(4,5-dimethyl-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (inner salt)
(MTS). The MTS assay was performed with the CellTiter 96 AQueous
One Solution cell proliferation assay system (Promega) according to the
manufacturer’s instructions. Briefly, 100 l of medium/well was trans-
ferred to a 96-well plate and incubated with 20 l of a substrate solution
(One Solution reagent) for 3 h in a CO2 (5%) incubator at 37°C. A blank
TABLE 1 Baseline characteristics of the macaques in the present study
Animal Treatment group MHC I
4890 ART-auranofin-BSO Mamu A*02*, Mamu B*17*
P157 ART-auranofin-BSO Mamu A*11*
4416 ART-auranofin Mamu A*02*
P185 ART-auranofin Mamu B*04*
P252 ART-BSO Mamu A*02*, Mamu B*03*
P177 ART-auranofin ART at rebound Mamu A*01*, Mamu B*01*
Shytaj et al.
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well, containing culture medium and One Solution reagent at the same
ratio, was included for each experiment. Absorbance levels were recorded
at 490 nm, and, following subtraction of the blank, data were normalized
over the levels of absorbance of the control well.
Measurement of intracellular GSH levels. To assess persistence of
-glutamylcysteine synthetase inhibition by BSO in vivo, intracellular glu-
tathione/glutathione disulfide (GSH/GSSG) was measured with a gluta-
thione assay kit (Sigma-Aldrich Italia, Milan, Italy) as previously de-
scribed (8). Briefly, PBMC samples (106 cells per sample) were
deproteinized with a 5% 5-sulfosalicylic acid solution, and their GSH
content was then measured using a kinetic assay. In this assay, catalytic
amounts of GSH cause a continuous reduction of 5,5=-dithiobis-(2-nitro-
benzoic) acid (DTNB) to TNB, shifting the color of the substrate. The
fluorescence of the reaction product (TNB) was measured at 412 nm.
Values were expressed as nanomoles of GSH in the original sample.
Measurement of gold levels in plasma. To assess persistence of aura-
nofin in plasma of treated macaques, we measured the concentration of
Au ions, given that Au is the basic mediator of the therapeutic effect of
auranofin and there is one Au atom per drug molecule. Biological samples
were prepared for analysis of Au content by digesting samples with 1 ml of
concentrated HNO3 and heated until clear. Two milliliters of water was
added, and the solutions were filtered through a 0.45-m GHP filter and
run on the Varian ICP-MS 820 instrument to determine the concentra-
tion of gold in each sample. Standards were prepared using HAuCl4 in
30% HNO3.
IFN- ELISpot assay. Cell-mediated immune responses in macaques
were detected by measuring gamma interferon (IFN-) secretion in an
enzyme-linked immunosorbent spot (ELISpot) assay. Macaque PBMCs
were stimulated with Gag peptides of SIVmac239, SIVsm, SIVver, and
HIV-1 (these peptides were obtained through the AIDS Research and
Reference Reagent Program, National Institutes of Health, Bethesda,
MD) and SIVsab (a kind gift of Cristian Apetrei, University of Pittsburgh,
Pittsburgh, PA). Peptides were resuspended in dimethyl sulfoxide
(DMSO) and pooled to span the whole Gag protein of each viral strain
employed in the analysis. Specifically, the following pools were used: two
pools for SIVmac239 Gag (pool 1, amino acids 1 to 263; pool 2, amino
FIG 1 Schematic representation of the treatments to which the macaques in the present study were subjected following viral load suppression through ART.
Chronically SIVmac251-infected macaques were previously treated with a highly intensified ART regimen (i.e., tenofovir, emtricitabine, raltegravir, ritonavir-
boosted darunavir, and maraviroc) to suppress viral loads and mimic the condition of HIV-positive individuals under ART (10). Following viral load suppres-
sion, auranofin was added to ART, with or without BSO and/or short ART cycles at posttherapy viral rebound (11). These intermittent ART cycles were originally
aimed at inducing an immunity against the virus (2, 4) Gray and black arrows indicate, respectively, the timing of BSO administration and of viral rebound
following the last treatment suspension.
Correlates of Posttherapy Viremic Control in Monkeys
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acids 253 to 510), two pools for SIVsab (pool 1, amino acids 1 to 283; pool
2, amino acids 273 to 556), two pools for SIVver (pool 1, amino acids 1 to
267; pool 2, amino acids 257 to 520), one pool for SIVsm (amino acids 1 to
500), and one pool for HIV-1 group M subtype C (amino acids 1 to 490).
Additionally, four smaller pools were employed for the analysis of the
conserved regions of the SIVmac239 Gag: conserved pool 1 (amino acids
149 to 171), conserved pool 2 (amino acids 225 to 251), conserved pool 3
(amino acids 257 to 371), and conserved pool 4 (amino acids 392 to 436).
All assays were performed with the ELISpotPRO kit for detection of mon-
key IFN- (Mabtech AB, Nacka Strand, Sweden) according to the manu-
facturer’s instructions.
Briefly, 1.5  105 Ficoll-isolated macaque PBMCs were added to 96-
well plates precoated with an anti-human/monkey IFN- antibody
(monoclonal antibody [MAb] GZ-4). Cells were resuspended in RPMI
1640 plus 10% FBS with or without 2 g/ml of each peptide pool or,
alternatively, with concanavalin (2 g/ml) or -CD3 (0.1 g/ml) as pos-
itive controls. Triplicate wells were employed for each experimental con-
dition. After 48 h of incubation at 37°C with 5% CO2, the cells were rinsed
from the plates, and a biotinylated anti-human/monkey IFN- antibody
(MAb 7-B6-1; Mabtech) was added to the wells. The plates were then
washed with PBS and incubated with the substrate solution (5-bromo-4-
chloro-3-indolylphosphate [BCIP]/nitroblue tetrazolium [NBT]-plus).
Spot-forming cells (SFC) were counted using an automated reader (Im-
munospot reader; CTL Analyzers, LLC, Cleveland, OH). Data were ex-
pressed as the average number of SFC/106 cells  standard error of the
mean (SEM) after subtracting from individual values the average number
of background spots detected in the negative controls.
Detection of neutralizing antibodies.To assess the humoral response
against the virus, the levels of neutralizing antibodies in sera from differ-
ent time points during the study were measured as described previously
(11). The TZM-bl assay system was employed for the analyses (17), using
a neutralization-sensitive (SIVmac251.6) and a neutralization-resistant
(SIVmac251.30) pseudotyped virus. Virus pseudotyped with murine leu-
kemia virus Env (SVA-MLV) was included to assess non-SIV-specific
neutralizing activity in the sera. Briefly, serial dilutions of sera from the
indicated time points were preincubated with the viruses (ca. 150,000
relative light unit equivalents) for 1 h at 37°C. Following addition of
TZM-bl target cells, the cultures were incubated for 48 h and then lysed
and assayed for luciferase activity. Neutralization titers are the sample
dilution at which relative luminescence units (RLU) were reduced by 50%
(ID50) compared to RLU in virus control wells after subtraction of back-
ground RLU in cell control wells. In several instances, ID50 endpoint titers
against SIVmac251.6 were not achieved in the dilution series employed in
the assays. Thus, an 80% neutralization titer (ID80) was calculated to
expose the relative potency of the neutralizing antibody response against
this virus.
Quantitative assay for SIVmac251 viral RNA levels.To quantify viral
replication in vivo, plasma SIVmac251 RNA levels were measured by real-
time nucleic acid sequence-based amplification (NASBA) assay, as previ-
ously described (18–20). The interassay coefficient of variation of the
technique was 19% (11), well within the limits of the typical interassay
variability of SIV RNA detection techniques (see, e.g., references 10 and
21). The values obtained were periodically validated using two different
real-time-PCR techniques as previously described in (10, 22).
Quantitative assay for SIVmac251 viral DNA. In order to have a sur-
rogate marker for the viral reservoir, total viral DNA was measured by
real-time PCR in two different centers, i.e., Bioqual, Inc., and ABL. For the
main analyses, conducted at Bioqual, Inc., DNA was extracted with the
phenol-chloroform method as previously described (10, 11). Quantifica-
tion was performed by amplifying a region of the gag gene by real-time
PCR in a 7700 sequence detection system (Applied Biosystems, Foster
City, CA, USA). The detection limit of this assay is two copies of viral
DNA/5  105 cells. Technical details and validations of the assay have
been provided previously (10).
The analyses at ABL were conducted as described previously (19, 23).
Briefly, genomic DNAs from tissues were isolated with the DNeasy blood
and tissue kit (Qiagen, Valencia, CA, USA) according to the manufactur-
er’s protocol, except for a modification at the DNA elution step (19). The
SIV gag gene and the macaque albumin gene sequence (the latter used as
an internal control) were amplified by real-time TaqMan qPCR technol-
ogy in a 7500 real-time system (Applied Biosystems). The normalized
value of the SIV viral DNA load was calculated as SIV DNA copy number/
macaque albumin gene copy number  2  106 and expressed as the
number of SIV viral DNA copies per 106 PBMCs (23).
Viral sequencing. Viral sequencing was performed to monitor viral
evolution (sequencing of the C2-V3 region of gp130) and to monitor
immune escape (sequencing of gag).
For the former, RNA was extracted from plasma samples, and the SIV
env gene was then reverse transcribed and PCR amplified from the plasma
RNA with the SIV versions of the primers described previously (24). Py-
rosequencing of the C2-V3 region was performed on PCR amplicons, i.e.,
amplified from gp130 env DNA fragments. Briefly, nested PCR products
for sequencing were generated using the external products described
above as templates with custom-designed fusion oligonucleotides that
contained the 454 adaptor sequences (Roche Lib-A primer A and primer
B), followed by a 10-base-pair multiplex identifier (MID) sequence to
permit sample pooling and finally SIV template-specific oligonucleotides.
Samples were quantified by fluorometry with the Quant-iT PicoGreen
double-stranded DNA (dsDNA) assay kit (Life Technologies), pooled in
equimolar concentrations, and sequenced on a 454 GS Junior System
(Roche Diagnostics) using the GS Junior titanium sequencing chemistry.
The resulting reads were trimmed to exclude the MIDs and primer se-
quence, and low-quality reads were filtered using the GS run processor
according to length and quality scores.
Sequencing of gag was performed as described previously (25). Briefly
viral RNA in plasma was isolated with the QIAamp MinElute virus spin kit
(Qiagen, Valencia, CA) according to the manufacturer’s instructions.
Viral RNA was reverse transcribed and amplified using the one-step re-
verse transcription-PCR kit (Qiagen), generating amplicons spanning
SIVmac239. Bulk Sanger sequencing was performed on an ABI 3730xl
DNA analyzer using ET terminator technology (GE Healthcare). Se-
quences were assembled against the SIVmac239 reference sequence
(GenBank accession number M33262) and conceptually translated using
CodonCode Aligner version 3.7.1.1 (CodonCode Corporation) and
MacVector 11.1 trial version (MacVector, Inc.).
Bioinformatic analyses. Multisequence alignments of reads of the
C2-V3 region and neighbor-joining phylogenetic trees were constructed
using BioEdit and ClustalX and using MUSCLE (PMID 15034147), and
MEGA5 (PMID 21546353) for maximum-likelihood analyses.
For multisequence alignments of the Gag proteins from different pri-
mate lentiviruses, sequences were retrieved from the NCBI website and
aligned with Clustal Omega (EMBL-EBI), and sequence distances were
visualized using phylogeny.fr (26).
Statistical analyses. Differences between variables were calculated us-
ing parametric tests (Student’s t test for comparisons between two groups
and analysis of variance [ANOVA] followed by an appropriate posttest for
multiple comparisons). An appropriate transformation was applied to
restore normality, where necessary. Repeated-measures tests were used
when analyzing matched observations. Trends were analyzed by regres-
sion analysis, followed by the extra sum-of-squares F posttest. Calcula-
tions were conducted using the software GraphPad Prism 5.00.288
(GraphPad Software, Inc., San Diego, CA, USA).
Multivariate analysis was used to study the contributions of indepen-
dent predictors to the posttherapy viral load set point and the difference
between the pre- and posttherapy viral load set points (	 viral set point).
The analysis was conducted with the IBM SPSS software (v. 21; IBM,
Armonk, NY, USA), using a type I regression parameter and, as dependent
variables, the posttherapy viral set point (calculated as the median of the
available measurements) and the 	 viral set point (calculated as a log
difference between the pre- and posttherapy viral set points). The choice
Shytaj et al.
7524 jvi.asm.org August 2015 Volume 89 Number 15Journal of Virology
 o
n
 January 8, 2016 by ARCURI
http://jvi.asm.org/
D
ow
nloaded from
 
of the potentially predicting parameters was based on extensive literature
analysis. Possibly independent predictors were considered to be the num-
ber of drugs simultaneously employed, the administration of peculiar
drugs such as mefloquine or the -CD8 monoclonal antibody, the total
duration of therapy (i.e., the number of days during which macaques were
exposed to drugs), the number of therapeutic cycles, and the pretherapy
CD4 nadir. A “therapy” was considered to be a sequence of therapeutic
cycles where the time between neighboring treatments did not exceed 90
days.
RESULTS
Auranofin and BSO kill activated T lymphocytes in vitro. In
previous studies (4, 8), we showed that auranofin induced apop-
tosis and downmodulation of the markers of long-lived pheno-
types, i.e., CD27 and CD28, in resting TCM and TTM cells. Addition
of BSO, however, did not enhance annexin V stainability or CD27
downmodulation in nonactivated central and transitional mem-
ory T cells (data not shown).
Based on a previous report showing that the combination of
auranofin and BSO impacted T-cell activation in vitro more than
auranofin alone (14), we decided to explore this path by examin-
ing the effects of BSO on the life span of lymphocytes treated with
auranofin for 24 h and subsequently activated. When activated
with -CD3 and -CD28 antibodies for 48 h, human CD4 and
CD8 T cells that had received auranofin and BSO displayed
lower expression of CD25, as previously reported (14), and higher
annexin V stainability (Fig. 2A; see Fig. S1 in the supplemental
material) than controls left untreated or treated with single agents.
This effect was paralleled by failure of the two-drug-treated cells to
form rosettes (Fig. 2B; see Fig. S1 in the supplemental material).
CD4 and CD8 T cells treated with auranofin alone showed
partial failure to express CD25 and form rosettes, whereas BSO
alone had little or no effect on these phenomena (Fig. 2A and B;
see Fig. S1 in the supplemental material). The ability of auranofin
to reduce activation induced by -CD3 and -CD28 stimulation
is consistent with the downmodulating effect of this drug on the
expression of CD28 previously reported in T lymphocytes (8).
CD4 and CD8 T cells treated with auranofin and BSO even-
tually exhibited very low cell viability at 72 h (Fig. 2C and D).
Auranofin alone decreased cell viability at 72 h, but this effect was
weaker than that induced by the two-drug combination (Fig. 2C
FIG 2 Treatment with auranofin (AF) and buthionine sulfoximine (BSO) reduces CD25 levels and activation of T lymphocytes in vitro. CD4 and CD8 T cells
were isolated from whole blood and left untreated or treated with AF (250 nM), BSO (250 M), or a combination of the two. At 24 h posttreatment, cells were
activated with-CD3 and-CD28 antibodies. (A) Levels of CD25 and annexin V measured at 48 h postactivation (data are from CD4T cells). (B) Photographs
taken at 72 h postactivation (CD4 T-cell cultures). (C and D) Viability of CD4 (C) (6 donors) and CD8 (D) (3 donors) T cells, as measured with the MTS
assay at 72 h postactivation. Values are means SEM. *, P
 0.05; **, P
 0.01; ***, P
 0.001.
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FIG 3 Treatment with auranofin and BSO reduces levels of HLA-DR in T lymphocytes at viral rebound. Levels of HLA-DR were measured by flow cytometry
and are displayed as percentages of HLA-DR CD4 (squares) and HLA-DRCD8 (circles) T cells. (A to C) The posttreatment data refer to the time frame
following suspension of ART-auranofin-BSO (A), ART-auranofin (B), and ART-BSO (C). The gray arrows indicate the approximate time of viral rebound. (D)
Proportions of HLA-DR CD4 (squares) and HLA-DR CD8 (circles) T cells closest to the viral rebound. Data include an additional macaque subjected to
ART plus auranofin without BSO (P177; not shown in the figure). Probit transformation was applied to normalize the percentage values to a scale of to,
suitable for parametric test analyses. *, P
 0.05; **, P
 0.01.
Shytaj et al.
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and D). BSO alone did not exert any significant effect on cell
viability.
Similar results were obtained when CD4 and CD8 T cells
were activated with phytohemagglutinin (PHA) (see Fig. S2 in the
supplemental material). We conclude that T lymphocytes treated
simultaneously with auranofin and BSO fail in the normal activa-
tion process and die.
Auranofin and BSO decrease T-lymphocyte activation in
vivo. We recently conducted a small but controlled study in
chronically SIVmac251-infected rhesus macaques (11) aimed at
showing the impact of auranofin and BSO (administered before
stopping ART) on posttherapy viral load control. Macaques that
were progressing to AIDS or that were derived from other studies
in which potentially therapeutic strategies had failed were treated
with a highly intensified ART, either alone or in combination with
auranofin (11). Of the latter animals, (i) two did not receive any
further treatment and were kept untreated following therapy sus-
pension, (ii) two received further short ART cycles at viral re-
bound after therapy suspension to limit viral reseeding, and (iii)
two received an eventual cycle of BSO before ART and auranofin
were suspended (treatments are summarized in Fig. 1 and Table
1). One of the animals of the second group received BSO during
the last of the further short ART cycles, but, in contrast to the
schedule applied to the third group, BSO was administered in the
absence of auranofin. This schedule allowed us to preliminarily
distinguish between the additive and synergistic effects of the two
drugs in vivo.
Using frozen PBMC samples from these macaques, we inves-
tigated whether the in vitro killing effects of the auranofin-BSO
combination on activated T lymphocytes were associated with
decreased numbers of activated cells in vivo during the post-
therapy viral rebound. As a tool to measure the frequency of acti-
vated T lymphocytes, we chose the widely validated activation
marker HLA-DR (27). We found that the macaques that had re-
ceived ART, auranofin, and BSO displayed a lower frequency of
HLA-DR T lymphocytes at viral rebound (Fig. 3). Subsequently,
CD8 T cells became activated, and their activation levels were
maintained throughout the follow-up. In contrast, CD4 T-cell
activation was maintained at lower levels than those for CD8 T
cells, with periodic increases that were transient. In contrast, fol-
lowing suspension of ART plus auranofin or ART plus BSO, there
was a higher level of lymphocyte activation at viral rebound that
was more marked in the CD4 T-cell compartment. The activa-
tion level in these control macaques was maintained stably over
time or, in one macaque, dropped during progression to AIDS
(Fig. 3), in line with the immune deficiency and lymphocyte an-
ergy characterizing the later stages of the disease (28, 29). We
conclude that monkeys that had received the combination of au-
ranofin and BSO were characterized by low-level T-cell activation
at viral rebound.
We then aimed at investigating how the drug effects would be
exerted following therapy suspension. We therefore measured the
persistence of the drug effects during the posttherapy period (Fig. 4).
Concentration of glutathione in PBMCs is the most reliable clinical
indicator for the activity of BSO, which is an irreversible inhibitor of
-glutamyl cysteine synthetase (a limiting-rate enzyme in glutathione
FIG4 In vivo levels of glutathione and gold before, during, and after treatment with auranofin and BSO. (A) Concentration of total glutathione (i.e., GSH/GSSG,
the molecule[s] depleted by BSO) in PBMCs of the two macaques (4890 and P157) that received auranofin and BSO (squares) and in the macaque (P252) that
received BSO separately from auranofin (circles). The arrow shows the approximate timing of viral rebound following therapy suspension. Data are expressed as
means SEM (calculated from the values from the macaques that received auranofin and BSO [squares]). (B) Concentration of gold (i.e., the active principle
of auranofin) in the plasma of four treated macaques. The dotted line shows the concentration of auranofin employed in the in vitro experiments described in this
article. Data are expressed as means SEM. For details about dosages and schedule of administration of auranofin and BSO see Fig. 1, Table 1 and reference 11.
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FIG 5 Posttherapy development of broadly reactive anti-Gag immune responses in macaques treated with ART-auranofin-BSO. (A) Cell-mediated immune
responses against the Gag antigens of various simian and human lentiviruses. The viruses employed are SIVmac239 (N portion and C portion, light and dark blue,
respectively), SIVsm (red), SIVsab (N portion and C portion, ochre and orange, respectively), SIVver (N portion and C portion, light and dark green,
respectively), and HIV-1 (purple). (B) Phylogenetic tree constructed on the basis of the Gag amino acid sequences of primate lentiviruses. Highlighted are the
viruses used for the ELISpot analyses. Gag sequences from the following viruses were used to generate the tree: SIVsab, host Chlorocebus sabaeus (accession
Shytaj et al.
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synthesis) (30). Glutathione was maintained at low levels (similar to
those observed in our in vitro treatments [data not shown]) for 1
month after BSO administration (Fig. 4A). At 2 months posttherapy,
one of the macaques (4890) experienced a major increase in glutathi-
one, which may be due to a compensatory increase, whereas the other
two macaques receiving BSO maintained decreased GSH levels com-
pared to baseline (Fig. 4A).
Measurement of the plasma levels of the gold ion [Au(I)], i.e.,
the active principle of auranofin, showed that the metal persisted
at therapeutic concentrations for at least 2 months following ther-
apy suspension (Fig. 4B). Persistence of the drugs, or their effects,
thus overlapped with the initial posttherapy viral rebound, which
is likely to be a key event for the subsequent virus/host dynamics.
On the whole, these data show that the combination of auranofin
and BSO, but not the two drugs administered separately, decreases
the numbers of activated T lymphocytes during viral rebound and
that the “functional cure”-like condition is preceded by T-cell
activation dynamics different from those in macaques progressing
to AIDS.
Decreased numbers of activated T lymphocytes are accom-
panied by the emergence of broadly reactive anti-Gag cell-me-
diated responses. Cell-mediated immune responses against Gag
have consistently been shown to negatively correlate with viral
load (31–35). As our macaques displayed enhanced levels of im-
munity against the Gag antigen following treatment with ART,
auranofin, and BSO (11) (see Fig. S3 in the supplemental mate-
rial), we decided to better characterize this immune response by
analyzing whether the epitopes targeted were evolutionarily con-
served. We reasoned that epitopes which underwent little or no
change through the evolution of different lentiviral strains were
likely to be fundamental for viral fitness and thus be effective tar-
gets, which could account for the long-term intermittent viral
load control displayed by the macaques following suspension of
ART, auranofin, and BSO. We analyzed the responses of the
PBMCs of the macaques that had received ART-auranofin-BSO to
stimulation with Gag peptides of distinct primate lentiviruses,
such as SIVsm from sooty mangabeys (Cercocebus atys), SIVsab
from African green monkeys (Chlorocebus sabaeus), SIVver from
vervet monkeys (Chlorocebus pygerythrus), and HIV-1 from hu-
mans (subtype C). We found that the responses were cross-reac-
tive to various degrees, with the strongest cross-reactivity being
observed with SIVsm (Fig. 5A), in line with the close phylogenetic
relationship of this virus with SIVmac (Fig. 5B). In the same phy-
logenetic tree (Fig. 5B) the SIVsab strain clustered separately from
the other strains infecting African green monkeys (i.e., SIVver,
SIVgri, and SIVtan), in accordance with the previously described
mosaic structure of the genetic material of SIVsab (36). Notably,
both macaques also showed cross-reactivity against SIVver and
more tenuous responses toward SIVsab and HIV-1, with the latter
being more evident in macaque 4890 (Fig. 5A; see Fig. S4 in the
supplemental material). Given the ability of PBMCs of rhesus ma-
caques to respond upon stimulation with antigens of viruses re-
lated to, yet significantly different from, SIVmac251, we conclude
that the immune responses evoked by auranofin and BSO in vivo
were broadly cross-reactive.
To further analyze these broadly reactive responses, our next
step was to test whether the highly conserved regions of Gag might
be the main target of the immune responses following treatment
with auranofin and BSO. Guided by sequence alignments (see
Text S1 in the supplemental material), we selected four highly
conserved regions of Gag and analyzed the IFN- response to
peptide pools corresponding to these regions. Two peptide pools
(i.e., corresponding to conserved regions CR1 and CR2, spanning
amino acids 149 to 171 and 225 to 251, respectively) lay in the
N-terminal half and two (i.e., corresponding to conserved regions
CR3 and CR4, spanning amino acids 257 to 371 and 389 to 439,
respectively) in the C-terminal half of the Gag antigen (note that
the C-terminal half of Gag displays a higher degree of evolutionary
conservation [see Text S1 in the supplemental material]). Our
analyses showed that the strongest responses were evoked by CR3
(Fig. 5C; see Fig. S5 in the supplemental material). Of note, titers
of neutralizing antibodies did not show any association with the
therapeutic effects observed (see Fig. S6 in the supplemental ma-
terial).
The emergence of broadly reactive anti-Gag cell-mediated
responses is accompanied by IFN- responses in natural killer
cells. While this article was being prepared, Scott-Algara et al. (37)
reported significant IFN- responses in natural killer (NK) cells of
posttreatment controllers from the VISCONTI cohort (i.e., individ-
uals who had started ART early during acute infection and had been
subjected to treatment interruption). Therefore, we aimed at investi-
gating whether these phenomena might also occur in the macaques
that had received auranofin and BSO. Our results showed that ma-
caques that had received auranofin and BSO simultaneously had de-
tectable IFN- responses in CD56 cells upon stimulation with Gag
peptides at at least one time point of the posttreatment follow-up
(Fig. 6). No responses were observed posttreatment in the macaques
that had received auranofin without BSO (Fig. 6). One macaque that
had received auranofin and BSO separately (P252) showed, in the
posttreatment period, an intermediate frequency of Gag-specific
CD56 IFN- cells (Fig. 6).
Extended follow-up of macaques that had received aura-
nofin-BSO. As mentioned in the previous sections, our earlier
study showed an intermittent control of viral load only in those
number U04005.1); SIVsm, host Cercocebus atys (accession number AF334679.1); HIV-2, host Homo sapiens (accession number A14062.1); SIVmac239, host
Macacamulatta (accession number AY611495.1); SIVver, host Chlorocebus aethiops (accession number M30931.1); SIVtan, host Chlorocebus tantalus (accession
number U58991.1); SIVgri, host Chlorocebus pygerythrus (accession number M66437.1); SIVgor, host Gorilla gorilla (accession number FJ424871.1); HIV-1
(subtype C), host Homo sapiens (accession number AX457080.1); SIVcpz, host Pan troglodytes (accession number JN091691.1); SIVsun, host Cercopithecus
solatus (accession number AF131870.1); SIVlhoest, host Cercopithecus lhoesti (accession number AF075269.1); SIVolc, host Procolobus verus (accession number
AM713177.1); and SIVcol, host Colobus guereza (accession number AF301156.1). The recently sequenced Gag from ELVgv, an endogenous lentivirus from
Galeopterus variegatus (orderDermoptera) (50) was used as an outgroup. The tree was constructed with phylogeny.fr (as described in reference 26) using a Clustal
 alignment. (C) Cell-mediated immune responses against peptide pools encompassing conserved regions of the C-terminal half of the SIVmac239 Gag protein
(i.e., CR3 and CR4; see Text S1 in the supplemental material). The sequences of the conserved regions employed for the analysis are shown in Text S1 in the
supplemental material. Immune responses were measured by IFN- ELISpot. The ELISpot data are expressed as number of spot-forming cells (SFC)  106
PBMCs. The ratio of conserved responses over the total is calculated, for each time point, as a sum of the mean number of SFC detected with CR3 and CR4
peptides divided by the mean number of SFC detected with peptides spanning the C-terminal half of the Gag.
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macaques that had been treated with ART, auranofin, and BSO
simultaneously, although all macaques that had received aura-
nofin showed some varying degree of control of viral load follow-
ing treatment suspension (11). To explore the long-term effects of
the virus/immune system dynamics induced by treatment with
auranofin and BSO, we subjected to extended follow-up the only
two macaques from our cohort (11) that had been simultaneously
treated with ART, auranofin, and BSO. Thereafter, both macaques
had shown intermittent viral load control (11), and no further
treatment cycles were administered during the entire follow-up
period.
One macaque (P157), which had shown in the posttherapy
period a viral set point consistent with elite control (i.e., 
5,000
copies of viral RNA/ml [25]), was subjected to CD8 cell deple-
tion at 42 weeks posttherapy, when viral load in plasma and vag-
inal liquids was undetectable, as previously described (11). Se-
quencing of the gag gene following CD8 T-cell depletion
revealed a homogeneous wild-type Gag, identical to the ancestral
SIVmac239 Gag sequence (data not shown), thus supporting the
aforementioned hypothesis that targeting of the highly conserved
regions that are fundamental for correct protein folding limits the
virus evolutionary options. In this macaque, however, the original
CD8 T-cell numbers never recovered (before depletion, 1,022
274 [mean standard deviation {SD}]; after depletion, 396 204
cells/l) (see Fig. S7 in the supplemental material), leading to
partial loss of immune control despite maintenance of detectable
anti-Gag immunity (mean number of spot-forming cells [SFC]/
106 PBMCs 1,072 677 [mean SD]). Instead, the number of
CD4 T cells was kept relatively stable after a transient decrease
observed during the early stages of the CD8 T-cell depletion
(before depletion, 896 228; after depletion, 886 411, cells/l
[mean  SD]) (see Fig. S7 in the supplemental material). When
we compared the viral loads in the same macaque after CD8 cell
depletion with the pretherapy viral load data for this macaque as
measured by the same technique (NASBA), we found that despite
the low levels of CD8 T cells, the viral load was maintained at a
level approximately one order of magnitude lower than the pre-
therapy viral set point (respectively, 4.14  0.17 log10 viral RNA
copies/ml versus 5.04 0.20 log10 viral RNA copies/ml [mean
SEM; P 0.0165 by two-tailed t test]) (Fig. 7A). The posttherapy
viral loads were double-checked with another technique, i.e., real-
time PCR (see Table S1 in the supplemental material). At the time
of euthanasia, the animal did not show any AIDS-related signs
or symptoms, and its weight had increased by 15%, compared
to the pretherapy values (data not shown). Our anti-CD8 treat-
ment was aimed at showing a transient increase in viral load,
similar to that observed in the model described by Pandrea et
al. (38). The unforeseen incomplete recovery of CD8 T cells
and partial loss of viral load control induced us, for both ethical
and investigational reasons, not to apply the same depletion to
the other animal that had received the combined treatment
with ART, auranofin, and BSO.
This other macaque (4890) displayed, from week 43 post-
therapy, a viral set point below the detection limit (Fig. 7B), and
this was confirmed by independent testing in three different lab-
oratories (see Table S1 in the supplemental material). Viral DNA
in PBMCs, a widely accepted surrogate marker of the viral reser-
voir (39, 40), also gradually declined over time (see Fig. S8 in the
supplemental material). The result of the extended follow-up thus
showed a scenario that was, in the long term, very similar to that
observed with the other auranofin-BSO-treated macaque (P157),
which had shown undetectable or low-level viral DNA before it
was subjected to CD8 cell depletion (11). Moreover, CD4 T
cells of macaque 4890 gradually increased following the initial
consumption that had been observed during the acute-infection-
like condition at viral rebound following therapy suspension (see
Fig. S8 in the supplemental material). Of note, apart from cellular/
molecular analyses, the consistent weight increase displayed by
macaque 4890 following therapy suspension is in line with the
absence of disease progression (see Fig. S8 in the supplemental
material). Samples from week 49 to week 92 were subjected to
further validations with different assays in distinct locations (see
Table S1 in the supplemental material), which confirmed the
overall trends.
Treatment with ART-auranofin-BSO is followed by mainte-
nance of limited viral diversity or gradual loss of viral quasispe-
cies. Because following treatment with ART, auranofin, and BSO,
the macaques showed periodic viral blips (Fig. 7), we character-
ized the virus that emerged during these blips. For this purpose,
we performed next-generation 454 pyrosequencing of the viral
populations in plasma samples corresponding to selected blips.
Based on estimates of viral load or inefficiencies in RNA extrac-
tions and/or reverse transcription steps, we estimated that a min-
imum of 100 SIVmac RNA copies (per plasma sample) were se-
quenced per bar-coded primer set. Based on 1,000 sequence
reads, we obtained 10 oversampling of the SIVmac population
at each time point. Finally we sequenced the variable C2/V3 region
of the viral envelope gp130 glycoprotein to ensure a high SIVmac
diversity. The resulting viral quasispecies can be visualized with
neighbor-joining trees (Fig. 8) or similar maximum-likelihood
trees (data not shown; sequences are available upon request).
Macaque P157 displayed only one haplotype per peak after the
initial viral rebound. Phylogenetic analysis showed that the dom-
inant SIVmac haplotypes at different peaks were quite genetically
distinct (2 to 14 nucleotide substitutions in a 365-nucleotide se-
FIG 6 Macaques that had received ART, auranofin, and BSO displayed higher
posttherapy levels of Gag-specific, IFN--producing natural killer (NK) cells
than control animals. PBMCs were stimulated with SIV-specific Gag peptides
for 24 h to evaluate T-cell-dependent production of IFN- by CD56NK cells.
Data are expressed as a mean range. Time points were selected on the basis
of the documented presence of ELISpot responses and on sample availability.
Shytaj et al.
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quence read), suggesting that the distinct haplotypes were not a
consequence of 454 read error and not due to ongoing slow evo-
lution caused by continuous virus replication. Instead, these find-
ings suggest multiple events of reactivation from latency in the
interpeak period. Interestingly, during the viral rebound that ac-
companied CD8 cell depletion, four main viral quasispecies
emerged, suggesting that the diversity of the viral reservoir may
have been controlled by the CD8 cell-mediated immunity.
In macaque 4890, a certain degree of viral diversity appeared
during the initial viral rebound (Fig. 8). However, despite an at-
tempt to escape immunity detected during the blip at 40 weeks
posttherapy, the number of viral quasispecies decreased, and
thereafter, the virus detected during each blip became homoge-
neous (Fig. 8), in line with the decrease in viral DNA (see Fig. S8 in
the supplemental material). Interestingly, at 1 year after therapy
suspension, the dominant virus emerging during the blip was very
close to the ancestral SIVmac251 sequence, suggesting reactiva-
tion from a long-lived reservoir (Fig. 8). Taken together, these
data show that inhibition of T-cell activation at viral rebound
followed by broadly reactive anti-Gag cell-mediated responses
was associated with maintenance of low-level viral diversity.
A retrospective analysis of a cohort of 19macaques supports
the efficacy and safety of auranofin-BSO regimens. We finally
aimed at giving a statistical confirmation of the therapeutic effects
observed. We therefore tested, by multivariate analysis, the out-
comes of a series of treatments, consisting of antiretroviral drugs,
auranofin, BSO, and CD8 cell depletion, within a cohort of 19
SIVmac251-infected macaques subjected to several related treat-
ments (references 4, 10, and 11 and unpublished data). Treatment
outcome was considered in terms of viral set point reduction (	
viral set point) and posttherapy viral set point. The analysis con-
firmed that parameters associated with the viral reservoir size
(e.g., inhibition of initial reseeding of viral reservoir through short
ART cycles at viral rebound; P  0.033), with immune contain-
ment of viral load (absence of CD8 cell depletion; P  0.001),
and with inhibition of T-cell activation (administration of the
complete treatment consisting of 5-drug ART, auranofin, and
BSO; P 
 0.001) were significantly associated with posttherapy
decrease of the viral set point (see Table S2 in the supplemental
material). Furthermore, nadir CD4 T-cell counts (P  0.002),
which identify the viral reservoir (41), but not pretherapy viral
loads (P 0.520), also contributed to the extent of the 	 viral set
point (see Table S2 in the supplemental material). This analysis
confirms the working hypothesis that a functional cure is contrib-
uted by (i) a restricted viral reservoir, (ii) restricted CD4 T-cell
activation, and (iii) efficient CD8 immune responses. Moreover,
ELISpot and sequencing data support the hypothesis that viral
load containment is likely to be contributed by the aforemen-
FIG 7 Long-term follow-up of viral load in macaques treated with ART-auranofin-BSO. Posttherapy viral loads are shown as circles. The posttherapy viral set
points in the follow-up period after our previous publication (11) are shown by the brackets. Pretherapy viral set points are shown by the dashed horizontal lines
and are based on all available measurements starting from 30 weeks before the initiation of ART. Both pre- and posttherapy viral set points are based on NASBA
assay measurements (limit of detection, 50 copies of viral RNA/ml of plasma). Viral loads outside the brackets (not included in the analysis) are shown for clarity’s
sake and are aimed at aiding the reader in the historical understanding of the entire posttherapy follow-up. For macaque P157, the viral loads outside the brackets,
and not included in the present analysis, were measured with a different technique (i.e., real-time PCR; limit of detection, 40 copies of viral RNA/ml of plasma
[11]). The areas shaded in gray correspond to the periods in which a definition for elite control was applicable (25) and are characterized by an undetectable viral
load set point.
Correlates of Posttherapy Viremic Control in Monkeys
August 2015 Volume 89 Number 15 jvi.asm.org 7531Journal of Virology
 o
n
 January 8, 2016 by ARCURI
http://jvi.asm.org/
D
ow
nloaded from
 
FIG 8 Viral diversity following suspension of ART-auranofin-BSO. The trees show the viral quasispecies detected in plasma during different viral load peaks
following therapy suspension. The time point analyzed and the relative frequency of the given quasispecies during that time point are shown. The analysis was
performed by 454 pyrosequencing of the C2-V3 region of the env gene. The figure presents only unique quasispecies over a 1% frequency, i.e., set by the
approximate error rate of 454 pyrosequencing and quantity of RNA templates (51).
Shytaj et al.
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tioned parameters and not to be dependent on the genetic back-
ground of the animals (see Text S2 in the supplemental material).
DISCUSSION
Based on the results shown in the present article, it is possible to
hypothesize that decreased T-cell activation is a key component
for a functional cure of HIV/AIDS (42), along with viral reservoir
reduction and broadly reactive cell-mediated responses. Based on
the evidence presented here, we propose a reconstruction of the
events leading to the posttreatment viral load containment de-
scribed in the present paper, as follows.
(i) Previously published data showed that viral reservoir reduc-
tion obtained by inducing selective apoptosis in the memory com-
partment using a combination of auranofin and ART resulted in a
decrease of the viral load set point. However, this did not lead to
control of the viral load to undetectable levels (4). That a limited
viral reservoir alone is insufficient for obtaining such a condition
is also shown by the recent cases of the “Mississippi baby” and the
“Boston patients” (5, 6), as well as controlled studies in macaques
(3, 4). It appears that the absence of any specific immunity allows
a limited number of infected cells to restore disease progression.
(ii) From our retrospective analysis, addition of BSO to aura-
nofin, carrying out further immune-modulating effects by de-
creasing intracellular glutathione, appeared to be essential for ob-
taining prolonged, albeit intermittent, posttherapy control of the
viral load in our macaques. The in vitro data presented here show
a decreased life span of activated T lymphocytes after treatment
with auranofin and BSO. In vivo, the auranofin levels and gluta-
thione depletion persisted at least for 1 month after drug with-
drawal. Thus, if the viral load peak that we observed during the
first viral rebound were a novel acute infection-like condition, as
we hypothesized previously (for a review, see reference 43), its
timing might fall into the therapeutic window of the drugs, influ-
encing the subsequent course of the infection. In particular, the
decrease in activated T lymphocytes that we show in the present
study may have limited, at viral rebound, the immune exhaustion
linked to immune hyperactivation which occurs during disease
progression (44, 45).
(iii) Decreased numbers of activated T cells may at first glance
appear to be contradictory to the broadly reactive cell-mediated
responses characterizing the intermittent but prolonged control
of the infection that ensued. Our result, however, is in line with
recent research supporting the concept that activation of immu-
nodominant responses may hamper more efficient responses di-
rected toward conserved Gag epitopes (13). One possibility is that
reduction of immune activation at viral rebound may have ham-
pered major histocompatibility complex (MHC)-restricted im-
munodominant responses toward epitopes capable of escaping
the immune response through mutations. An alternative/comple-
mentary hypothesis is that during the initial viral rebound, the
selective pressure exerted by auranofin and BSO on the SIV-acti-
vated T-cell clones would induce the preferential survival of the
responses toward the most frequent antigens, i.e., the highly con-
served epitopes of Gag, which are less likely to mutate due to
structural constraints (46). These immune responses are in line
with maintenance of low-level viral diversity over time and failure
of the virus to evolve phenotypes distant from those of the aborig-
inal virus. This may have ensured the prolonged decreased viral set
point that we observed.
We are well aware that the present study presents some limita-
tions, such as the fact that it was conducted in macaques, not in
humans, and with a relatively low number of animals employed.
We address these as follows. (i) The exceptional length of the
follow-up, driven by the necessity to assess the long-term efficacy
of the therapy (i.e., the only parameter which can yield the prom-
ise of a meaningful improvement over current ART for life), sig-
nificantly increased the costs of the study, hampering the expan-
sion of the numbers at this stage. (ii) The multivariate analysis
reported here, which took into account a large cohort of animals
that had received a wide array of similar, but yet incomplete, ther-
apeutic interventions, provides strong statistical support for the
notion that the posttreatment effects were specifically associated
with the auranofin-BSO combination. (iii) This conclusion is also
supported by ELISpot and sequencing analyses excluding the con-
tribution of an MHC class I genetic background to the result ob-
tained. (iv) Moreover, when dramatic changes in disease progres-
sion are clearly associated with the timing and striking benefit of a
treatment, limited numbers have previously been considered to be
acceptable (2, 47–49), given their potential role in opening new
therapeutic avenues. Finally, our preliminary data indicate that, in
contrast to from control animals, macaques that had received
ART, auranofin, and BSO displayed detectable posttherapy levels
of Gag-specific, IFN--producing natural killer (NK) cells. If this
early observation is confirmed with larger animal cohorts, it
would represent an interesting resemblance to HIV-positive indi-
viduals from the VISCONTI cohort experiencing a functional
cure of the disease following therapy suspension. These phenom-
ena will need to be explored by future research.
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